DN 028
Alternative Names: DN-028Latest Information Update: 01 Sep 2022
At a glance
- Originator Shanghai De Novo Pharmatech
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 28 Jul 2022 Early research in Solid tumours in China (Parenteral) (Shanghai De Novo Pharmatech pipeline, July 2022)